Mesoblast Limited (ASX: MSB; OTC ADR:MBLTY) is developing biological therapies for the emerging field of regenerative medicine.
Mesoblast's patented adult stem cell technology platform is built upon the discovery of adult-derived Mesenchymal Precursor Cells (MPCs).
The Company is commercialising patented MPC-based products for large clinical indications such as cardiovascular and neurological conditions, diabetes, eye diseases, cancers of the blood, bone fractures, cartilage degeneration and musculoskeletal conditions. These are all rapidly growing, billion dollar markets.
Business Model
Mesoblast's business model is very similar to classical pharmaceutical drug development: to deliver effective products with low manufacturing costs of goods and high margins.
This has been achieved as a result of two technical advantages that are unique to Mesoblast's patented stem cell technology - the ability of the cells to be greatly expanded and their lack of immunogenicity when used from one donor to treat many unrelated recipients.
The outcome is to generate industrially scaled-up allogeneic or 'off-the-shelf' products for use in thousands to tens of thousands of patients from a small amount of starting material obtained from a single healthy adult donor.
Point of difference
Mesoblast's technology positively selects for a starting population of MPCs which is more than 1000-fold purer than that of its competitors. Mesoblast's MPCs have been shown in clinical and preclinical studies to both create new blood vessels and stimulate cells at the site of damage to repair themselves, as well as providing recruitment of functional cells to the region of tissue in need of repair.
Cephalon strategic alliance
Mesoblast has entered into a strategic alliance with global biopharmaceutical company, Cephalon Inc., to develop and commercialise its adult stem cell therapeutics for degenerative conditions of the cardiovascular and central nervous systems. The alliance also extends to products for augmenting bone marrow transplantation in cancer patients.
Intellectual Property
The United States Patent and Trade Mark Office has granted key patents that deliver major commercial advantages and offer long term protection for the company's platform technology including a foundation patent for composition-of-matter, or ownership, over the MPCs; exclusive commercial protection for Mesoblast's bone tissue generating products; and manufacturing patents covering methods of purifying, isolating and enriching the MPCs. Additional patents have been filed covering specific uses of the companies' biologic products that considerably extend the duration of patent protection.
updated 26th August, 2011
| © Copyright 1996-2012 irasia.com Ltd. All rights reserved. |
|
DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any
information provided on this website. Under no circumstances shall irasia.com Ltd be liable
for damages resulting from the use of the information provided on this website.
TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for use on this website. All rights under applicable laws are hereby reserved. Reproduction of this website in whole or in part without the express written permission of irasia.com Ltd is strictly prohibited. TERMS OF USE: Please read the Terms of Use governing the use of our website. |